Collegium Pharmaceutical Inc (NASDAQ:COLL) is scheduled to post its quarterly earnings results before the market opens on Tuesday, August 8th. Analysts expect Collegium Pharmaceutical to post earnings of ($0.81) per share for the quarter.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.98) by $0.19. Collegium Pharmaceutical had a negative return on equity of 74.27% and a negative net margin of 1,062.52%. The business had revenue of $2.17 million during the quarter, compared to analyst estimates of $3.55 million. On average, analysts expect Collegium Pharmaceutical to post $-3.13 EPS for the current fiscal year and $-1.96 EPS for the next fiscal year.

Shares of Collegium Pharmaceutical Inc (COLL) opened at 11.32 on Monday. Collegium Pharmaceutical Inc has a 12-month low of $7.37 and a 12-month high of $20.55. The company’s market cap is $333.46 million. The firm’s 50-day moving average price is $12.18 and its 200 day moving average price is $12.12.

In other Collegium Pharmaceutical news, insider Paul Brannelly purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 12th. The stock was purchased at an average price of $9.18 per share, for a total transaction of $91,800.00. Following the purchase, the insider now directly owns 110,227 shares in the company, valued at $1,011,883.86. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.76% of the stock is owned by insiders.

A number of research firms have weighed in on COLL. Needham & Company LLC reduced their price objective on Collegium Pharmaceutical from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, May 11th. BidaskClub lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday. Piper Jaffray Companies set a $14.00 price target on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, July 25th. Jefferies Group LLC restated a “buy” rating and issued a $22.00 price target (down previously from $24.00) on shares of Collegium Pharmaceutical in a research note on Thursday, May 11th. Finally, Zacks Investment Research lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Three research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $21.33.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Stock Ratings for Collegium Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc and related stocks with our FREE daily email newsletter.